



**edap tms**  
Bringing New Horizons to Therapy

## **EDAP TMS SA to Announce Fourth Quarter 2021 Financial Results on Wednesday, March 30, 2022**

March 21, 2022

*Company to host conference call and webcast on Thursday, March 31, at 8:30 am ET*

**LYON, France, March 21, 2022** - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the fourth quarter ended December 31, 2021 after the markets close on Wednesday, March 30, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am ET on Thursday, March 31, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

### **Conference Call & Webcast**

#### **Thursday, March 31<sup>st</sup> @ 8:30am Eastern Time**

Domestic: 877-451-6152

International: 201-389-0879

Passcode: 13727107

Webcast: [https://viaavid.webcasts.com/starthere.jsp?ei=1529371&tp\\_key=b54f335485](https://viaavid.webcasts.com/starthere.jsp?ei=1529371&tp_key=b54f335485)

### **About EDAP TMS SA**

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, and [us.hifu-prostate.com](http://us.hifu-prostate.com).

### **CONTACTS:**

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

+33 4 72 15 31 50

[bconfort@edap-tms.com](mailto:bconfort@edap-tms.com)

Investor Contact

John Fraunces

LifeSci Advisors, LLC

917-355-2395

[jfraunces@lifesciadvisors.com](mailto:jfraunces@lifesciadvisors.com)